Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Inhibitors & Agonists > Others

Others

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC5084 Telenzepine
Potent and selective M1 antimuscarinic
More description
DCC5083 Teixobactin
Natural antibacterial agent, being active against gram-positive bacteria.
More description
DCC5081 Tefinostat
Novel monocyte/macrophage targeted histone deacetylase inhibitor
More description
DCC5079 Tdr32570
Novel antimalarial agent
More description
DCC5078 Tdp222669
Novel inhibitor of the p53-Hdm2 protein-protein interaction, dose-dependently stabilized P53 and increased P21 and MDM2 expression in JAR choriocarcinoma cells, inducing the p53 regulated gene (PIG-3) and caspase activity
More description
DCC5077 Tdp1-in-9a
Novel potent inhibitor of tyrosyl-DNA phosphodiesterase 1 (Tdp1)
More description
DCC5076 Tdmq20
Novel Specific Copper Chelator, Reducing Memory Impairments in Alzheimer's Disease Mouse Models
More description
DCC5075 Tdcipp
Hepatotoxicity inducer, significantly up-regulating the expression of genes involved in endoplasmic reticulum stress and Toll-like receptor (TLR) pathway
More description
DCC5074 Td-5471 Hydrochloride
Novel long-acting β 2 -adrenoceptor agonist
More description
DCC5073 Td-428
Novel potent BET protein degrader, inhibiting cell proliferation due to suppressed C-MYC transcription
More description
DCC5072 Td-1211
Novel selective opioid receptor antagonist at all three receptor types
More description
DCC5071 Td-106
Novel IKZF1/3 degrader, inhibiting the proliferation of multiple myeloma cells in vitro as well as in vivo
More description
DCC5070 Td-004
Novel degrader of the anaplastic lymphoma kinase (ALK) fusion protein, effectively inducing ALK degradation and inhibiting the growth of ALK fusion positive cell lines, SU-DHL-1 and H3122, significantly reducing the tumor growth in H3122 xenograft model
More description
DCC5069 T-cupm
Sorafenib analogue, retaining cytotoxicity similar to sorafenib in various human cancer cell lines and strongly inhibiting growth in the NCI-60 cell line panel
More description
DCC5068 Tc-t 6000
Potent equilibrative nucleoside transporter 4 (ENT4) inhibitor
More description
DCC5067 Tcs-401
Insulin receptor sensitizing agent; Selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B)
More description
DCC5066 Tcs-3035
Novel GPR35 agonist
More description
DCC5064 Tcs2312
Novel potent and selective CHK1 kinase inhibitor
More description
DCC5063 Tc-s 7005
Potent and selective polo-like kinase 2 (PLK2) inhibitor
More description
DCC5062 Tc-ot-39
Nonpeptide partial agonist of oxytocin (OT) and vasopressin V2 receptors
More description
DCC5061 Tcn-237 Dihydrochloride
Highly potent NR2B-selective NMDA receptor antagonist
More description
DCC5060 Tcmdc-135051 Tfa Salt
Novel Inhibitor of the malaria parasite protein kinase CLK3, inhibiting the development of liver-stage parasites, killing asexual blood-stage parasites at the trophozoite and schizont stages of the erythrocytic cycle, blocking the development of sexual ga
More description
DCC5059 tcmdc-125802
Antimalarial; Novel inhibitor of HepG2
More description
DCC5058 Tc-i 2014
Potent TRPM8 antagonist, exhibiting antiallodynic properties in pain models
More description
DCC5056 Tch-013
Non-competitive modulator of the proteasome inducing apoptosis a panel of myeloma and leukemia cell lines
More description
DCC5055 Tc-g1004
Potent and selective antagonist of adenosine A2A receptors
More description
DCC5053 Tc-e 5006
Novel orally bioavailableγ-secretase modulator, reducing Aβ42 levels
More description
DCC5052 tc-c-14g
Potent CB1 receptor inverse agonist
More description
DCC5051 Tc-aqp1-1
Aquaporin 1 (AQP1) channel blocker
More description
DCC5050 Tc-ac28
Novel potent and selective ligand of Brd2(2)
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X